{"disease":{"id":"hepatic-chemotherapy","name":"hepatic chemotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06641713","title":"HAIC Compared With TACE in Huge Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":664,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07277192","title":"HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival","phase":"","overall_status":"COMPLETED","enrollment_count":562,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT04764409","title":"Prevention and Treatment of Complications of Endovascular Methods in Patients With Malignant Liver Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Central Clinical Hospital RZD-Medicine, Russian Federation","has_results":false},{"nct_id":"NCT06898398","title":"TACE Combined Surgery for the Resectable Huge HCC","phase":"","overall_status":"RECRUITING","enrollment_count":326,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06333561","title":"HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06631326","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT06632106","title":"HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT07436845","title":"Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06632093","title":"HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","phase":"","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT05416073","title":"Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"The Second Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT05025592","title":"cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07062055","title":"BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT06567600","title":"Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Third Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07327788","title":"QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07353827","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06184841","title":"HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}